Dermira (NASDAQ:DERM) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Dermira (NASDAQ:DERM) from a hold rating to a strong-buy rating in a report published on Wednesday, Zacks.com reports. Zacks Investment Research currently has $6.50 price target on the biopharmaceutical company’s stock.

According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “

Separately, BidaskClub lowered Dermira from a hold rating to a sell rating in a research report on Tuesday, October 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $17.36.

Shares of DERM stock opened at $5.69 on Wednesday. The stock has a fifty day moving average of $7.59 and a 200 day moving average of $9.49. Dermira has a 52 week low of $5.30 and a 52 week high of $15.48. The firm has a market capitalization of $309.54 million, a price-to-earnings ratio of -1.09 and a beta of 1.32. The company has a quick ratio of 8.08, a current ratio of 8.42 and a debt-to-equity ratio of 4.95.

Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.57. Dermira had a negative return on equity of 478.29% and a negative net margin of 306.91%. The company had revenue of $66.65 million during the quarter, compared to analyst estimates of $34.16 million. Equities research analysts anticipate that Dermira will post -4.42 earnings per share for the current year.

In other news, CEO Thomas G. Wiggans acquired 23,419 shares of the stock in a transaction on Monday, August 19th. The stock was acquired at an average price of $8.54 per share, with a total value of $199,998.26. Following the completion of the transaction, the chief executive officer now owns 39,666 shares of the company’s stock, valued at approximately $338,747.64. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Matthew K. Fust sold 6,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $8.77, for a total value of $52,620.00. Following the transaction, the director now directly owns 11,051 shares of the company’s stock, valued at approximately $96,917.27. The disclosure for this sale can be found here. Company insiders own 12.40% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Hong Kong Ltd raised its position in shares of Dermira by 124.2% in the 2nd quarter. Point72 Hong Kong Ltd now owns 4,170 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 2,310 shares during the last quarter. Bank of Montreal Can raised its position in shares of Dermira by 621.8% in the 2nd quarter. Bank of Montreal Can now owns 4,533 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 3,905 shares during the last quarter. Advisor Group Inc. raised its position in shares of Dermira by 41.7% in the 2nd quarter. Advisor Group Inc. now owns 8,589 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 2,527 shares during the last quarter. Atria Investments LLC purchased a new position in shares of Dermira in the 2nd quarter worth about $85,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Dermira in the 2nd quarter worth about $120,000. 94.53% of the stock is owned by hedge funds and other institutional investors.

About Dermira

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Further Reading: What is a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Dermira (DERM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.